NASDAQ : INKT
MiNK Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 10.875 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 55.50M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 6.62M | 6.73M | 4.31M | 7.43M | 7.83M | 4.64M |
| Research & Development | 5.75M | 5.76M | 6.34M | 15.49M | 23.12M | 13.97M |
| Other Operating Expenses | -377.18K | 154.83K | 638.05K | |||
| Operating Expenses | 11.99M | 12.64M | 11.29M | 22.92M | 30.95M | 18.61M |
| Operating Income | -11.99M | -12.64M | -11.29M | -22.92M | -30.95M | -18.61M |
| Interest Expense | -2.43M | |||||
| Interest & Investment Income | 320.10K | 180.25K | 172.57K | 463.26K | 253.32K | |
| Currency Exchange Gain (Loss) | 339.62K | -407.00K | ||||
| Other Non Operating Income (Expenses) | -32.37K | -32.37K | 145.91K | -10.00 | -86.07K | 628.92K |
| EBT Excluding Unusual Items | -11.36M | -12.49M | -10.97M | -22.46M | -30.78M | -20.82M |
| Gain (Loss) on Sale of Assets | 185.00K | |||||
| Other Unusual Items | 2.79M | -9.40M | ||||
| Pretax Income | -11.36M | -12.49M | -10.78M | -22.46M | -27.99M | -30.21M |
| Net Income | -11.36M | -12.49M | -10.78M | -22.46M | -27.99M | -30.21M |
| Net Income to Common | -11.36M | -12.49M | -10.78M | -22.46M | -27.99M | -30.21M |
| Shares Outstanding (Basic) | 4.74M | 4.27M | 3.77M | 3.44M | 3.37M | 2.60M |
| Shares Outstanding (Diluted) | 4.74M | 4.27M | 3.77M | 3.44M | 3.37M | 2.60M |
| EPS (Basic) | -2.40 | -2.93 | -2.86 | -6.54 | -8.31 | -11.61 |
| EPS (Diluted) | -2.40 | -2.93 | -2.86 | -6.54 | -8.31 | -11.61 |
| Free Cash Flow | -6.83M | -5.93M | -9.56M | -15.84M | -19.12M | -13.08M |
| Free Cash Flow Per Share | -1.44 | -1.39 | -2.53 | -4.61 | -5.68 | -5.02 |
| EBITDA | -11.83M | -12.46M | -11.07M | -22.72M | -30.83M | -18.53M |
| D&A For EBITDA | 154.35K | 181.75K | 215.44K | 204.62K | 121.75K | 77.96K |
| EBIT | -11.99M | -12.64M | -11.29M | -22.92M | -30.95M | -18.61M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 8.81M | 13.36M | 4.58M | 3.37M | 19.64M | 38.89M |
| Cash & Short-Term Investments | 8.81M | 13.36M | 4.58M | 3.37M | 19.64M | 38.89M |
| Prepaid Expenses | 277.57K | 276.43K | 246.60K | 53.11K | 298.67K | 1.76K |
| Other Current Assets | 212.22K | 211.20K | 164.24K | 177.96K | 470.30K | 744.32K |
| Total Current Assets | 9.30M | 13.85M | 4.99M | 3.60M | 20.40M | 39.63M |
| Property, Plant & Equipment | 318.47K | 390.87K | 732.93K | 953.98K | 1.07M | 606.60K |
| Total Assets | 9.62M | 14.24M | 5.72M | 4.55M | 21.47M | 40.24M |
| Accounts Payable | 3.92M | 3.43M | 2.73M | 3.91M | 5.82M | 3.00M |
| Accrued Expenses | 1.20M | 1.58M | 1.87M | 5.04M | 4.24M | 1.76M |
| Current Portion of Long-Term Debt | 5.18M | |||||
| Other Current Liabilities | 2.45M | 2.85M | 2.36M | 2.45M | 2.62M | 11.71M |
| Total Current Liabilities | 7.57M | 13.03M | 6.96M | 11.40M | 12.68M | 16.47M |
| Long-Term Debt | 4.92M | |||||
| Other Long-Term Liabilities | 16.07M | 15.44M | 13.42M | 11.21M | 9.19M | |
| Total Liabilities | 23.64M | 28.47M | 25.31M | 22.61M | 21.87M | 16.47M |
| Common Stock | 52.00 | 48.00 | 40.00 | 35.00 | 339.00 | 335.00 |
| Additional Paid-In Capital | 149.22M | 143.17M | 125.23M | 115.77M | 110.83M | 107.35M |
| Retained Earnings | -162.55M | -156.68M | -144.18M | -133.40M | -110.94M | -82.95M |
| Comprehensive Income & Other | -699.89K | -718.92K | -631.58K | -430.95K | -292.47K | -625.27K |
| Shareholders' Equity | -14.03M | -14.23M | -19.59M | -18.06M | -401.30K | 23.78M |
| Total Liabilities & Equity | 9.62M | 14.24M | 5.72M | 4.55M | 21.47M | 40.24M |
| Total Debt | 5.18M | 4.92M | ||||
| Net Cash (Debt) | 8.81M | 8.18M | -347.57K | 3.37M | 19.64M | 38.89M |
| Net Cash Per Share | 1.86 | 1.92 | -0.09 | 0.98 | 5.83 | 14.94 |
| Filing Date Shares Outstanding | 5.10M | 4.97M | 3.97M | 3.47M | 3.39M | 3.36M |
| Total Common Shares Outstanding | 5.10M | 4.71M | 3.96M | 3.46M | 3.39M | 3.35M |
| Working Capital | 1.73M | 816.52K | -1.97M | -7.80M | 7.72M | 23.17M |
| Book Value Per Share | -2.75 | -3.02 | -4.94 | -5.22 | -0.12 | 7.10 |
| Tangible Book Value | -14.03M | -14.23M | -19.59M | -18.06M | -401.30K | 23.78M |
| Tangible Book Value Per Share | -2.75 | -3.02 | -4.94 | -5.22 | -0.12 | 7.10 |
| Machinery | 1.00M | 1.00M | 1.26M | 1.45M | 1.35M | 775.20K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -11.36M | -12.49M | -10.78M | -22.46M | -27.99M | -30.21M |
| Depreciation & Amortization | 154.35K | 181.75K | 215.44K | 204.62K | 121.75K | 77.96K |
| Loss (Gain) From Sale of Assets | 2.70K | 169.80K | -185.35K | |||
| Stock-Based Compensation | 2.24M | 2.67M | 1.81M | 3.86M | 3.03M | 1.74M |
| Other Operating Activities | -326.90K | 254.83K | -1.07M | -266.78K | -2.79M | 11.83M |
| Change in Accounts Payable | 606.56K | 689.71K | -1.18M | -1.92M | 2.66M | -152.04K |
| Change in Other Net Operating Assets | 1.85M | 2.60M | 1.64M | 4.81M | 6.11M | 3.89M |
| Operating Cash Flow | -6.83M | -5.93M | -9.56M | -15.76M | -18.87M | -12.83M |
| Capital Expenditures | -73.56K | -250.05K | -248.98K | |||
| Investing Cash Flow | -73.56K | -250.05K | -248.98K | |||
| Long-Term Debt Issued | 5.00M | 9.46M | ||||
| Net Debt Issued (Repaid) | -5.00M | 5.00M | 9.46M | |||
| Issuance of Common Stock | 19.41M | 14.90M | 5.82M | 70.47K | 1.59K | 46.00M |
| Repurchase of Common Stock | -425.12K | -173.35K | -477.64K | -157.19K | ||
| Other Financing Activities | -6.20M | |||||
| Financing Cash Flow | 13.99M | 14.72M | 10.82M | -407.17K | -155.60K | 49.26M |
| Foreign Exchange Rate Adjustments | -30.56K | -13.43K | -54.70K | -25.25K | 19.39K | 16.90K |
| Net Cash Flow | 7.13M | 8.78M | 1.21M | -16.27M | -19.25M | 36.20M |
| Free Cash Flow | -6.83M | -5.93M | -9.56M | -15.84M | -19.12M | -13.08M |
| Free Cash Flow Per Share | -1.44 | -1.39 | -2.53 | -4.61 | -5.68 | -5.02 |
| Levered Free Cash Flow | -5.35M | -4.23M | -8.62M | -11.08M | -20.25M | -8.67M |
| Unlevered Free Cash Flow | -5.35M | -4.23M | -8.62M | -11.08M | -20.25M | -7.15M |
| Cash Interest Paid | 10.06K | 9.52K | 13.13K | 27.51K | 10.82K | |
| Change in Working Capital | 2.46M | 3.29M | 459.73K | 2.90M | 8.77M | 3.74M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 56.34M | 52.34M | 27.62M | 36.94M | 88.18M | 149.43M |
| Enterprise Value | 47.53M | 43.78M | 25.90M | 30.54M | 64.02M | 214.03M |
| Last Close Price | 10.53 | 11.15 | 6.97 | 10.70 | 26.10 | 44.60 |
| PB Ratio | -3.68 | -1.41 | -2.05 | -219.74 | 6.29 | |
| P/TBV Ratio | 6.29 | |||||
| Debt / Equity Ratio | -0.36 | -0.25 | ||||
| Net Debt / Equity Ratio | 0.63 | 0.57 | -0.02 | 0.19 | 48.93 | -1.64 |
| Net Debt / EBITDA Ratio | 0.74 | 0.66 | -0.03 | 0.15 | 0.64 | 2.10 |
| Net Debt / FCF Ratio | 1.29 | 1.38 | -0.04 | 0.21 | 1.03 | 2.97 |
| Quick Ratio | 1.16 | 1.02 | 0.66 | 0.29 | 1.55 | 2.36 |
| Current Ratio | 1.23 | 1.06 | 0.72 | 0.32 | 1.61 | 2.41 |
| Return on Equity (ROE) | -239.50% | |||||
| Return on Assets (ROA) | -123.84% | -79.17% | -137.35% | -110.10% | -62.69% | -51.92% |
| Return on Capital Employed (ROCE) | -585.80% | -1,047.10% | 911.20% | 334.60% | -352.20% | -78.30% |
| Earnings Yield | -21.71% | -23.87% | -39.05% | -60.80% | -31.74% | -20.22% |
| FCF Yield | -12.81% | -11.32% | -34.60% | -42.87% | -21.68% | -8.75% |
| Buyback Yield / Dilution | -19.52% | -13.18% | -9.82% | -2.04% | -29.38% | -7.95% |